CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

CG Oncology

related news
Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

Reuters

April 18 2026
Pfizer Ventures gets behind OTR Therapeutics’s $100M series A to boost R&D hub’s capability

Fierce Biotech

December 05 2025

Get In Touch

Contact Us